Adalimumab pen bulk supplier for pharma manufacturers

Adalimumab Pen 40 mg/0.8 mL, 40 mg/0.4 mL Suppliers & Bulk Manufacturers

Available Forms: Pre-filled Syringe or Pen

Available Strengths: 40 mg/0.8 mL, 40 mg/0.4 mL

Reference Brands: Humira (US & EU), Exemptia (India)

Category: Arthritis

Adalimumab is a monoclonal antibody that binds to TNF-alpha, a cytokine involved in inflammation and immune response. It reduces inflammation, tissue damage, and symptoms in rheumatoid arthritis. Benefits include rapid symptom relief, improved joint function, reduced disease progression, and convenient subcutaneous administration, enhancing patient adherence and quality of life.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Adalimumab pen is approved in the EU and US for rheumatoid arthritis and other autoimmune diseases. In the EU, brands like Humira are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval is based on extensive clinical data, biosimilarity assessments, and pharmacovigilance. Both regions require detailed dossiers for approval and continued safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for adalimumab pens, ensuring adherence to European and American standards for safe, effective biologic therapy, and helping you navigate complex regulatory processes seamlessly.

Adalimumab Pen — third party manufacturing & bulk supply

Adalimumab Pen 40 mg/0.8 mL, 40 mg/0.4 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Adalimumab Pen is supplied as Pre-filled Syringe or Pen — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Adalimumab Pen listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Adalimumab Pen →

Back to Listing

Frequently Asked Questions

Adalimumab Pen is used to treat several autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and certain inflammatory conditions.

Adalimumab is a recombinant human monoclonal antibody that targets and blocks tumor necrosis factor-alpha (TNF-α), a substance in the body that causes inflammation in autoimmune diseases.

Common trade names include Humira, Amgevita, Hyrimoz, Idacio, Hadlima, Yuflyma, and Exemptia.

The original brand Humira was developed and marketed by the pharmaceutical company AbbVie, while several pharmaceutical companies produce biosimilar adalimumab products worldwide.

The generic name is Adalimumab.

Common brand names include Humira, Amgevita, Hyrimoz, Idacio, Hadlima, Yuflyma, and Exemptia.

Adalimumab Pen is manufactured in several countries including the United States, Germany, India, and other regions by different pharmaceutical manufacturers.